BIO 300 is being developed as an agent to improve outcomes for cancer patients undergoing radiation treatment for solid tumors. Radiation therapy is a leading curative treatment for solid tumors, but can have harmful side effects to normal tissues that are in the path of the beam or are adjacent to the tumor. BIO 300 has been shown to protect normal tissues from these side effects, while not protecting the tumor. Preclinical models also indicate that BIO 300 increases the killing effect of radiation on multiple tumor types. Preclinical and clinical programs are currently focused on Lung, Prostate and Head and Neck Cancers. Humanetics is receiving funding from the National Cancer Institutes for these programs. Learn more.
The U.S. Government and Military have prioritized the need for medical countermeasures for accidental or intentional radiological events. BIO 300 has received extensive funding from the Department of Defense and the Biomedical Research and Development Authority (BARDA). Learn more.
There is also significant interest in BIO 300 from NASA to protect astronauts from space radiation events during space flight. Humanetics has received grant funding from the National Space Biomedical Research Institute and direct from NASA to test the protective effects of BIO 300 against radiation encountered in deep space.